Corporate Presentation

Differentiated Imetelstat Profile in IMerge Phase 3 40% ≥ 8-wk RBC-TI response rate; 1-year median 3.6 g/dL median Hgb rise TI duration Robust & Durable Response 18% ≥ 1-yr RBC-TI response rate; 5.2 g/dL median Hgb rise 60% transfusion reduction by ≥4U/8 wks; 1.4 g/dL median Hgb rise RS+ and RS- geron 2.4 years median TI duration Broad Response Across MDS Subgroups High and very high transfusion burden 1.3 years duration SEPO level greater than or less than 500 mU/mL Platzbecker, Santini et al. The Lancet 2023 Additional IMerge data including placebo comparisons included on slides 10-17 Low or intermediate-1 IPSS risk category SSS IDA IMerge Additional Attributes 50% of imetelstat-treated patients reported less fatigue (PRO data) ≥50% VAF reduction in commonly mutated MDS genes experienced by more imetelstat-treated patients vs placebo Well Characterized Safety Profile the most common adverse events were thrombocytopenia and neutropenia that were manageable and of short duration 9

View entire presentation